Background For a decade, anti-interleukin-5/receptor α (IL5/Rα) has been available to treat severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid burden. However, little is known about long-term, real-world sustained remission.
We aimed to assess the stability of response to anti-IL5/Rα over 5 years. Methods All Danish adults initiating anti-IL5/Rα for severe asthma during January 2016 through June 2020 were included.
Five-domain remission (no exacerbations, no maintenance oral corticosteroid, forced expiratory volume in 1 s (FEV 1 ) >80% predicted, Asthma Control Questionnaire score Results In total, 482 patients were included (median age 56 years, 48% female). At baseline, 13.9% fulfilled the criteria of no exacerbations, 66.0% of no maintenance oral corticosteroid, 29.7% of FEV 1 >80% predicted and 26.5% of Asthma Control Questionnaire score The overall remission rate was 17.6 - 23.1% over 5 years.
However, remission was found to be dynamic; approximately 15.2% of patients in remission per annum did not fulfil the remission criteria the subsequent year.
European Respiratory Journal published a clinical update in Critical Care on 12 Mar 2026.
The item focuses on Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/R{alpha} biologic therapy response for severe asthma.
Review the original article for the full source wording and details.